Category: Boston ScientificSyndicate content

Boston Scientific, other medtech giants weigh in on mega-mergers

July 29, 2014 by Arezu Sarvestani

A recent spate of mega-mergers hasn't inspired medtech peers to follow suit just yet, according to leadership at Boston Scientific, C.R. Bard and Smith & Nephew.

Boston Scientific, other medtech giants weigh in on mega-mergers

The medical device industry has some blockbuster merger activity in recent months, but a few companies are sitting this one out.

Medtech's top stent-makers land SharedClarity contracts

July 29, 2014 by Arezu Sarvestani

Healthcare-provider alliance SharedClarity signs some of medtech's biggest firms to land specialized pricing for peripheral stents.

Medtech's top stent-makers land SharedClarity contracts

Four of medtech's biggest firms agreed to offer peripheral stents at specialized prices to members of SharedClarity, an organization formed through the alliance of some of the country's largest health insurance and care providers.

Michigan judge shoots down settlement alleged by Biomet in poaching spat with Stryker | Medtech legal news for the week of July 28, 2014

July 28, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Judge nixes alleged settlement in Stryker, Biomet poaching spat; Boston Scientific loses bids to exclude testimony in pelvic mesh trials; Occlutech claims another win over St. Jude Medical; Align Tech declares a 'total win' as federal circuit reverses ITC ruling; Report: Medtronic shareholder sues to block Covidien merger

Judge nixes alleged settlement in Stryker, Biomet poaching spat

July 23, 2014 by Brad Perriello

Press Release: Boston Scientific receives CE Mark for Agent drug-coated balloon

July 24, 2014 by Arezu Sarvestani

Innovative technology adds to company's leading portfolio of treatment options for coronary artery disease.

Press Release: Boston Scientific receives CE Mark for Agent drug-coated balloon

Boston Scientific lands another E.U. win, this time for Agent balloon

July 24, 2014 by Arezu Sarvestani

Boston Scientific is on a regulatory roll, now touting CE Mark approval for its Agent drug-coated balloon for treatment of coronary artery disease.

Boston Scientific lands another E.U. win, this time for Agent balloon

Boston Scientific (NYSE:BSX) added another product to its recent string of regulatory approvals, announcing European CE Mark approval and immediate commercial launch for the company's Agent paclitaxel-coated balloon catheter.

Boston Scientific beats The Street with Q2 sales, earnings

July 24, 2014 by Brad Perriello

Boston Scientific beats Wall Street's expectations and its own forecasts for 2nd-quarter sales and earnings, with strong performances from its core implantable cardiac defibrillator and drug-eluting stent businesses.

Boston Scientific beats The Street with Q2 sales, earnings

Boston Scientific aims to simplify intravascular imaging with Polaris

July 22, 2014 by Arezu Sarvestani

The Massachusetts medtech giant launches commercial efforts for its Polaris imaging software, an upgrade to the iLab system that aims to be "smart, fast and accurate."

Boston Scientific aims to simplify intravascular imaging with Polaris

Boston Scientific (NYSE:BSX) today announced the commercial launch of its Polaris imaging software, an upgrade to the company's iLab system that aims to make intravascular imaging simpler and more powerful.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp